Rapid screening model for asthenia and use method

Abstract

The invention provides a rapid screening model for asthenia, a use method and a method for combined use of blood protein markers and asthenia phenotype indexes, and the rapid screening model comprises a basic data module, a calculation module and a result evaluation module, wherein the basic data module is divided into a blood protein marker evaluation sub-module containing gamma interferon (IFN gamma), a granulocyte colony stimulating factor (GCSF), a tumor necrosis factor alpha (TNF alpha) and the like, and a weakness phenotype index evaluation sub-module containing factors such as grip strength reduction, weight loss, fatigue, step speed reduction and the like. Through independent or combined analysis of the blood protein marker and the weakness phenotype index, rapid weakness screening can be carried out on old people.

Description

Technical Field

[0001] The present invention belongs to the field of biomedical technology, more specifically to the interdisciplinary field of geriatrics, public health, preventive medicine and epidemiology, and especially relates to the assessment of frailty status in the elderly population; a rapid screening model for frailty involving blood protein biomarkers and a method of use are constructed. Background Art

[0002] As the global aging problem becomes increasingly serious, the prevention and treatment of geriatric diseases has become the research focus of modern geriatric medicine. Frailty is a geriatric syndrome characterized by the decline of physiological reserve functions of multiple organ systems, decreased physiological energy storage, and reduced stress resistance with age. It can affect 10% of people over 65 years old and 25%-50% of people over 85 years old. The disease increases the incidence of falls, disability, delirium, cognitive impairment, depression, re-hospitalization, long-term care, and even death in the elderly, bringing serious health and economic burdens to families and society. Although there are no effective drugs for frailty except exercise and nutritional intervention, frailty can be prevented, and timely intervention in patients in the early stages of frailty can fully recover.

[0003] Therefore, effective screening and diagnosis of frailty in the elderly is a public health priority. However, there are great difficulties in the effective screening and diagnosis of frailty. There are currently two main methods to assess human frailty: the Fried phenotype method, which includes five indicators: fatigue, decreased grip strength, slow walking, reduced activity and weight loss, and the Rockwood Frailty Index method, which is mainly based on the theory of age-related defect accumulation.

[0004] Both of the above diagnostic tools are based on questionnaire scales in clinical practice, which are very time-consuming, subjective, and not suitable for simple, rapid, extensive and objective screening in the community or clinical practice.

[0005] Blood markers are widely used in many diseases because they are convenient and time-saving. However, there is no consensus on the blood markers of frailty reported in the literature, and their specificity and sensitivity are low. They have not yet been used in clinical practice, and there is an urgent need to improve the sensitivity and specificity of their detection. Summary of the invention

[0006] In view of the above problems, this application screens multiple protein indicators of clinical samples to obtain a set of effective blood markers for frailty, and combines them with traditional frailty phenotypic indicators to develop a rapid screening model and method for frailty with higher specificity, stronger sensitivity and more objective results.

[0007] The present invention provides a rapid screening model for frailty, which utilizes blood protein markers and / or frailty phenotype indicators to characterize and judge the screening. The model includes a basic data module, a calculation and judgment module, and a result output module. The basic data module signal is connected to the calculation and judgment module, and the calculation and judgment module signal is connected to the result evaluation module.

[0008] The basic data module comprises a data input submodule, a blood protein marker assessment submodule, and / or a frailty phenotype indicator assessment submodule;

[0009] The data input submodule obtains the concentration measurement data of blood protein markers and the frailty phenotype indicator data;

[0010] The blood protein marker evaluation submodule includes a first data comparison component and a first value assignment component. The concentration measurement characteristics of a plurality of blood protein markers are respectively compared one by one with the set threshold value by the first data comparison component, and the first value assignment component assigns a negative or positive value to the blood protein marker expression level data; if any two blood protein markers are evaluated and assigned a positive value, the first value assignment component assigns a hematological positive value, and if not, the first value assignment component assigns a hematological negative value;

[0011] The frailty phenotype index evaluation submodule includes a second data comparison component and a second value assignment component. A plurality of frailty phenotype index data are respectively compared one by one with the set threshold value by the second data comparison component, and the second value assignment component judges and assigns a value to the phenotype test result; ≥3 points are assigned as positive-frail stage, 1-2 points are assigned as positive-pre-frail stage, and 0 points are assigned as negative-no frailty;

[0012] The calculation and judgment module is used to determine the assignment results of the blood protein marker assessment submodule and the frailty phenotype index assessment submodule singly or in combination. The calculation module uses the assignment results of the blood protein marker assessment submodule for judgment; or, the calculation module judges the blood protein marker assessment submodule and the frailty phenotype index assessment submodule in combination, and if both are negative, the result is judged as no frailty; hematology positive + phenotype positive-frail stage result is judged as frailty; hematology positive + phenotype positive-pre-frailty result is judged as pre-frailty; hematology negative + phenotype positive-frail stage result is judged as frailty; hematology negative + phenotype positive-pre-frailty result is judged as pre-frailty; hematology positive + phenotype negative-no frailty result is judged as doubtful;

[0013] The result output module uses the first color to represent normal, the second color to represent the early stage of weakness, the third color to represent weakness, and the fourth color to represent doubt.

[0014] Further, the blood protein markers evaluated in the blood protein marker evaluation submodule in the basic data module include a combination of one or more blood protein markers of interferon-γ, granulocyte colony stimulating factor, or tumor necrosis factor-α. The above blood protein markers exist both in serum and in plasma. Therefore, these blood protein markers can also be identified as serum protein markers or plasma protein markers.

[0015] Furthermore, the parameters evaluated in the frailty phenotype indicator evaluation submodule in the basic data module include a combination of one or more characteristic indicators of a grip strength reduction parameter, a weight loss parameter, a fatigue frequency parameter, or a gait speed reduction parameter.

[0016] Furthermore, the threshold value set by the blood protein marker assessment submodule is the average value of blood tests, and the threshold value set by the frailty phenotype indicator assessment submodule is ≥3 points, which is assigned as positive-frail stage, 1-2 points, which is assigned as positive-early frailty, and 0 points, which is assigned as negative-no frailty.

[0017] Furthermore, the data input submodule of the basic data module inputs parameters through the device running the web page or the terminal application input interface; the calculation module is a device deployed in the cloud; and the result output module is a device running the web page or the terminal application.

[0018] The present invention also provides a method for using a rapid screening model for frailty, using any of the rapid screening models for frailty as described above, comprising the following steps:

[0019] A data input submodule is used to obtain the concentration measurement data of serum protein markers and the frailty phenotype indicator data, wherein the method for obtaining the concentration measurement data of blood protein markers includes collecting blood, separating blood, processing blood, measuring blood samples and obtaining blood protein markers, measuring the indicators of blood protein markers from the samples, detecting the expression level of each specific blood protein marker, and uploading the concentration measurement data of the input blood protein markers using the data input submodule; here, the blood can be arbitrarily separated into serum or plasma, and the expression level of specific serum protein markers or plasma protein markers can be detected.

[0020] The method of obtaining frailty phenotype indicator data includes filling out a frailty phenotype questionnaire or an on-site frailty phenotype test on a terminal device or online, and uploading and inputting the frailty phenotype indicator data using a data input submodule;

[0021] After the above basic data detection parameters are inputted into the terminal device or online, the terminal device or online outputs the weakening screening or judgment result, and the method is as follows:

[0022] The blood protein marker assessment submodule, the concentration measurement characteristics of several blood protein markers, judges the measurement results of each blood protein marker, and judges the results below the measurement threshold as positive, and makes a combined judgment on the results of each blood protein marker, wherein the results of any two blood protein markers being positive are judged as hematologically positive;

[0023] The frailty phenotype index assessment submodule judges the test results of several frailty phenotype index data, and assigns ≥3 points as positive-frail stage, 1-2 points as positive-pre-frail stage, and 0 points as negative-no frailty;

[0024] The calculation and judgment module is used to determine the assignment results of the blood protein marker assessment submodule and the frailty phenotype index assessment submodule singly or in combination. The calculation module uses the assignment results of the blood protein marker assessment submodule for judgment alone; or, the calculation module makes a combined judgment on the judgment and evaluation assignments of the blood protein marker assessment submodule and the frailty phenotype index assessment submodule. If both are negative, the result is judged to be no frailty; the result of hematology positive + phenotype positive-frail stage is judged to be frail; the result of hematology positive + phenotype positive-pre-frailty is judged to be pre-frailty; the result of hematology negative + phenotype positive-frail stage is judged to be frail; the result of hematology negative + phenotype positive-pre-frailty is judged to be pre-frailty; the result of hematology positive + phenotype negative-no frailty is judged to be questionable, and the result is output by the result output module.

[0025] Furthermore, the changes in the blood protein marker indicators of interferon-γ, granulocyte colony-stimulating factor, and tumor necrosis factor-α contained in the blood protein marker assessment submodule in the basic data module are obtained by enzyme-linked immunosorbent assay, Luminex-based multi-analysis spectrum analysis, single-molecule protein array detection, lateral flow immunoassay, nucleic acid aptamer technology, and proteomics assay.

[0026] Furthermore, characteristic indicators such as decreased grip strength, weight loss, fatigue, decreased gait speed, etc. included in the frailty phenotype assessment submodule in the basic data module are obtained through on-site consultation, online or terminal device questionnaires, or on-site testing.

[0027] Furthermore, in the calculation and judgment module, the change result of a single indicator is first judged, and then various indicators are combined, a certain threshold is set, and a single hematological indicator is used for judgment or a combination of hematology and frailty phenotype indicators is used for comprehensive judgment, and the result is input into the terminal device or online tool.

[0028] Furthermore, granulocyte colony stimulating factor and the frailty phenotype may be used alone in combination.

[0029] Compared with the prior art, the present invention has the following beneficial effects:

[0030] (1) The present invention, for the first time, uses the screened blood frailty markers, which can be used alone or in combination with traditional frailty phenotype indicators, to construct a rapid screening model for frailty, so as to improve the specificity, sensitivity and objectivity of screening for frailty in the elderly. It provides a new direction for the study of frailty. Therefore, the present invention overcomes the shortcomings of the existing frailty detection rate, long time consumption, etc., has the characteristics of good specificity and high sensitivity, and has good clinical application value for the auxiliary diagnosis of frailty. In particular, serum or plasma protein markers are used as biomarkers for the detection of frailty for the first time, which has great technical significance.

[0031] (2) The blood protein markers in the present invention are obtained and verified based on the screening of multiple common markers in clinical samples. They are not only highly representative, but also have good specificity and accuracy when used in combination.

[0032] (3) The combined use of some key factors in each basic data submodule in the present invention can greatly improve the efficiency of large-scale frailty screening. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 Flow chart for frailty screening in the elderly implemented for this application.

[0034] Figure 2 As an example, the results of screening for serum markers of frailty are shown.

[0035] Figure 3 As an example, the combination of frailty serum markers and frailty phenotype indicators improves screening specificity and sensitivity results.

[0036] Figure 4 As an example, some serum markers of frailty and some combinations of frailty phenotype indicators can be directly used for frailty screening.

[0037] Figure 5 This is a flow chart of the calculation and judgment module.

[0038] Figure 6 Schematic diagram of the module connection relationship of the rapid screening model for frailty. DETAILED DESCRIPTION

[0039] Before describing the present invention in detail, the definition of certain terms to be used herein is provided.Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art.

[0040] The term "subject" is intended to include any disorder that can be directly or indirectly involved in frailty. Examples of subjects include mammals, e.g., humans, non-human primates, dogs, cows, horses, pigs, sheep, goats, cats, mice, rabbits, rats, and transgenic non-human animals. In certain embodiments, the subject is a human, e.g., a human suffering from frailty, a human at risk of suffering from frailty and its associated diseases, or a human potentially capable of suffering from frailty-related diseases.

[0041] The terms "about" or "approximately" generally mean within 5%, or more preferably within 1% of a given value or range.

[0042] About Blood Protein Biomarkers for Frailty Screening

[0043] The present invention relates to blood protein biomarkers: compared with "normal" subjects, they are found to be differentially present in blood biological samples of subjects suffering from frailty. If the difference between the expression levels of a blood protein biomarker in the samples is determined to be statistically significant, then the blood protein biomarker is differentially present between samples. Blood protein biomarkers alone or in combination can be used to provide a measure of the relative risk of a subject suffering from frailty. Blood protein markers are present both in serum and in plasma. Therefore, these blood protein markers can also be identified as serum protein markers or plasma protein markers.

[0044] Take the determination of the expression level of blood protein biomarkers in serum in a sample as an example: that is, the level of serum protein biomarkers in a biological sample is determined by any suitable conventional method. Any reliable method for measuring the level or amount of serum protein biomarkers in a sample can be used. Generally, serum protein biomarkers can be detected and quantified from a biological sample, wherein the sample is a serum sample obtained by collecting whole blood from a subject, and the method includes: enzyme-linked immunosorbent assay, Luminex-based multi-analysis spectrum analysis, single molecule protein array detection, lateral flow immunoassay, nucleic acid aptamer technology and proteomics determination to obtain changes in serum protein marker indicators such as interferon-γ, granulocyte colony stimulating factor, and tumor necrosis factor α.

[0045] Take the determination of the expression level of blood protein biomarkers in plasma in a sample as an example: that is, the level of plasma protein biomarkers in a biological sample is determined by any suitable conventional method. Any reliable method for measuring the level or amount of plasma protein biomarkers in a sample can be used. Generally, plasma protein biomarkers can be detected and quantified from a biological sample, wherein the sample is a plasma sample obtained by collecting whole blood from a subject, and the detection method is used to obtain the index changes of markers such as interferon gamma, granulocyte colony stimulating factor, and tumor necrosis factor alpha in plasma.

[0046] Regarding the use of blood protein biomarkers to determine frailty, the basic principle is that frail people have different immune microenvironments from normal elderly people. Therefore, by studying the key differential factors in the immune microenvironments of the two, new blood screening or diagnostic tools for frailty can be developed. Therefore, the blood protein biomarkers described in the present invention can be used in diagnostic tests to assess the frailty status of subjects. The present invention also provides a method of combining hematological markers with frailty phenotypic fatigue alone or in combination, which indicates frailty and can be used to accurately determine frailty in subjects. The frailty phenotypic indicators are shown in Table 1 as an example:

[0047] Table 1 Fried frailty syndrome criteria

[0048]

[0049] The options are scored as 1 or 0 for "yes" or "no", with a total score of 0-5. The frailty phenotype status is calculated based on the score results: ≥

[0050] 3 points indicated positive-frail stage, 1-2 points indicated positive-pre-frail stage, and 0 point indicated negative-no frailty.

[0051] The purpose of the present invention is to develop a rapid screening method for frailty based on the combined application of hematological markers and frailty phenotype indicators, so as to facilitate medical staff to conduct rapid and objective screening or diagnosis of frailty in patients. Only serum protein markers are used as an example, but the process method can also be applied to plasma protein markers. The development process is as follows:

[0052] (1) Conduct physical examinations on a large number of elderly people in the community and screen out potential frail people through the frailty phenotype method.

[0053] (2) The ELISA method was used to evaluate dozens of potential frailty serum markers in the screened frail, pre-frail, and normal populations. Differential serum markers were screened, such as Figure 2 shown.

[0054] (3) Use a combination strategy for the screened serum markers to find a combination that can significantly improve specificity and sensitivity.

[0055] (4) Combine serological markers with frailty phenotype indicators to seek a combination with high specificity and high sensitivity.

[0056] The present invention provides a method based on a combination of blood protein markers and frailty phenotype indicators for rapid and objective screening of frailty in clinical practice. The rapid screening model for frailty specifically includes the following steps:

[0057] A data input submodule, for obtaining serum protein marker concentration measurement data and frailty phenotype indicator data, wherein the method for obtaining blood protein marker concentration measurement data includes collecting blood, separating serum or plasma, processing serum or plasma, measuring serum or plasma samples and obtaining serum protein markers or plasma protein markers, measuring indicators of serum protein biomarkers or plasma protein markers from samples, detecting the expression level of each specific serum protein marker or plasma protein marker, and uploading the input serum protein marker or plasma protein marker concentration measurement data using the data input submodule;

[0058] The method of obtaining frailty phenotype indicator data includes filling out a frailty phenotype questionnaire or an on-site frailty phenotype test on a terminal device or online, and uploading and inputting the frailty phenotype indicator data using a data input submodule;

[0059] After the above basic data detection parameters are inputted into the terminal device or online, the terminal device or online outputs the weakening screening or judgment result, and the method is as follows:

[0060] The blood protein marker assessment submodule, the concentration measurement characteristics of several blood protein markers, judges the measurement results of each blood protein marker, and judges the results below the measurement threshold as positive, and makes a combined judgment on the results of each blood protein marker, wherein the results of any two blood protein markers being positive are judged as hematologically positive;

[0061] The frailty phenotype index evaluation submodule judges the test results of several frailty phenotype index data, and assigns ≥3 points as positive-frail stage, 1-2 points as positive-pre-frail stage, and 0 points as negative-no frailty; Figure 5 shown.

[0062] The calculation and judgment module is used to determine the assignment results of the blood protein marker assessment submodule and the frailty phenotype index assessment submodule singly or in combination. The calculation module uses the assignment results of the blood protein marker assessment submodule for judgment alone; or, the calculation module makes a combined judgment on the judgment and evaluation assignments of the blood protein marker assessment submodule and the frailty phenotype index assessment submodule. If both are negative, the result is judged to be no frailty; the result of hematology positive + phenotype positive-frail stage is judged to be frail; the result of hematology positive + phenotype positive-pre-frailty is judged to be pre-frailty; the result of hematology negative + phenotype positive-frail stage is judged to be frail; the result of hematology negative + phenotype positive-pre-frailty is judged to be pre-frailty; the result of hematology positive + phenotype negative-no frailty is judged to be questionable, and the result is output by the result output module.

[0063] The present invention is further described below using serum protein markers as examples, but plasma protein markers may also be substituted, and the present invention is not limited thereto, and any conventional extensions that conform to the principles of the present invention belong to the scope of the present invention. The experimental methods in the following examples that do not specify specific conditions are usually carried out under conventional conditions or under conditions recommended by the manufacturer. Unless otherwise specified, the reagents and materials used in the following examples are commercially available.

[0064] Example 1

[0065] A single serological marker combination approach is used for rapid screening of frailty.

[0066] Step 1: Collect 3 ml of the patient's blood, centrifuge at 4°C, 2000g for 20 min, and dispense the upper serum into 1.5 ml sterile EP tubes. Each sample is dispensed into 3-4 tubes (about 1 ml / tube). Mark the name and number on the side of the tube and the tube cap, and freeze it in a -80°C refrigerator for later use.

[0067] Step 2: The concentrations of IFNγ, GCSF and TNFα in serum were tested by ELISA method.

[0068] Step 3: The measurement results of each factor IFNγ, GCSF and TNFα are judged, and the results below the measurement threshold are judged as positive.

[0069] Step 4: Combine the results of each factor of IFNγ, GCSF and TNFα, and the results of any two factors being positive are judged as positive for frailty.

[0070] Example 2

[0071] Rapid screening of frailty using a combination of serological markers and frailty phenotype indicators.

[0072] Step 1: Reference Figure 1 Process: Use terminal equipment or fill out the frailty phenotype questionnaire online, or perform on-site frailty phenotype test to test the patient's grip strength, weight, fatigue, gait speed and other phenotypes (as shown in Table 1).

[0073] Step 2: Collect 3 ml of the patient's blood and centrifuge at 2500 g to separate the serum.

[0074] Step 3: The concentrations of IFNγ, GCSF and TNFα in serum were tested by ELISA method.

[0075] Step 4: The measurement results of each factor IFNγ, GCSF and TNFα are judged, and the results below the measurement threshold are judged as positive.

[0076] Step 5: Combine the results of each factor of IFNγ, GCSF, and TNFα, and the results of any two factors being positive are judged as serologically positive.

[0077] Step 6: Judge the results of phenotypic tests such as grip strength, weight, fatigue, and gait speed. If any two of the indicators are positive, it is determined to be a positive frailty phenotype.

[0078] Step 7: Combine the serological results and the frailty phenotype results, and if both are positive, it is judged as frailty.

[0079] Example 3

[0080] A streamlined method combining serological markers GCSF and the frailty phenotype fatigue is used for rapid screening of frailty.

[0081] Step 1: Reference Figure 1 Process, use terminal equipment or fill in the results online to indicate whether the subject feels tired.

[0082] Step 2: Collect 3 ml of the patient's blood and centrifuge at 2500 g to separate the serum.

[0083] Step 3: ELISA method was used to test the concentration of GCSF in serum.

[0084] Step 4: The serum GCSF test results are judged, and the results below the test threshold are judged as serologically positive, and the results are entered into the terminal device or online tool.

[0085] Step 5: The cloud or terminal integrated device determines the combination of frailty phenotypic indicators and serological indicators. Patients with positive fatigue indicators and positive serological GCSF are diagnosed with frailty.

[0086] Step 6: The terminal device or online tool outputs the final frailty determination result.

[0087] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention is described in detail with reference to the aforementioned embodiments, those skilled in the art can still modify the technical solutions described in the aforementioned embodiments or replace some of the technical features therein by equivalents. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A rapid screening model for frailty, characterized in that: The combined characterization and judgment screening of blood protein markers and / or frailty phenotype indicators is used, and the model includes a basic data module, a calculation and judgment module, and a result output module. The basic data module signal is connected to the calculation and judgment module, and the calculation and judgment module signal is connected to the result evaluation module; The basic data module comprises a data input submodule, a blood protein marker assessment submodule, and / or a frailty phenotype indicator assessment submodule; The data input submodule obtains the concentration measurement data of blood protein markers and the frailty phenotype indicator data; The blood protein marker evaluation submodule includes a first data comparison component and a first value assignment component. The concentration measurement characteristics of a plurality of blood protein markers are respectively compared one by one with the set threshold value by the first data comparison component, and the first value assignment component assigns a negative or positive value to the blood protein marker expression level data; if any two blood protein markers are evaluated and assigned a positive value, the first value assignment component assigns a hematological positive value, and if not, the first value assignment component assigns a hematological negative value; The frailty phenotype index evaluation submodule includes a second data comparison component and a second value assignment component. A plurality of frailty phenotype index data are respectively compared one by one with the set threshold value by the second data comparison component, and the second value assignment component judges and assigns a value to the phenotype test result; ≥3 points are assigned as positive-frail stage, 1-2 points are assigned as positive-pre-frail stage, and 0 points are assigned as negative-no frailty; The calculation and judgment module is used to determine the assignment results of the blood protein marker assessment submodule and the frailty phenotype index assessment submodule singly or in combination. The calculation module uses the assignment results of the blood protein marker assessment submodule for judgment; or, the calculation module judges the blood protein marker assessment submodule and the frailty phenotype index assessment submodule in combination, and if both are negative, the result is judged as no frailty; hematology positive + phenotype positive-frail stage result is judged as frailty; hematology positive + phenotype positive-pre-frailty result is judged as pre-frailty; hematology negative + phenotype positive-frail stage result is judged as frailty; hematology negative + phenotype positive-pre-frailty result is judged as pre-frailty; hematology positive + phenotype negative-no frailty result is judged as doubtful; The result output module uses the first color to represent normal, the second color to represent the early stage of weakness, the third color to represent weakness, and the fourth color to represent doubt.

2. A rapid screening model for frailty according to claim 1, characterized in that: The blood protein markers evaluated in the blood protein marker evaluation submodule in the basic data module include a combination of one or more blood protein markers of interferon-γ, granulocyte colony stimulating factor, or tumor necrosis factor-α.

3. A rapid screening model for frailty according to claim 1, characterized in that: The parameters evaluated in the frailty phenotype index evaluation submodule in the basic data module include a combination of one or more characteristic indexes of a grip strength reduction parameter, a weight loss parameter, a fatigue frequency parameter, or a gait speed reduction parameter.

4. A rapid screening model for frailty according to claim 1, characterized in that: The threshold value set by the blood protein marker assessment submodule is the average value of blood tests, and the threshold value set by the frailty phenotype index assessment submodule is ≥3 points, which is assigned as positive-frail stage, 1-2 points, which is assigned as positive-early frailty, and 0 points, which is assigned as negative-no frailty.

5. A rapid screening model for frailty according to claim 1, characterized in that: The data input submodule of the basic data module inputs parameters through the device running the web page or the terminal application input interface; the calculation module is a device deployed in the cloud; and the result output module is a device running the web page or the terminal application.

6. A method for using a rapid screening model for frailty, characterized in that: Using the rapid screening model for frailty as described in any one of claims 1 to 5 comprises the following steps: A data input submodule, for obtaining blood protein marker concentration measurement data and frailty phenotype index data, wherein the method for obtaining blood protein marker concentration measurement data includes collecting blood, separating blood, processing blood, measuring blood samples and obtaining blood protein markers, measuring the index of blood protein markers from the samples, detecting the expression level of each specific blood protein marker, and uploading the input blood protein marker concentration measurement data using the data input submodule; The method of obtaining frailty phenotype indicator data includes filling out a frailty phenotype questionnaire or an on-site frailty phenotype test on a terminal device or online, and uploading and inputting the frailty phenotype indicator data using a data input submodule; After the above basic data detection parameters are inputted into the terminal device or online, the terminal device or online outputs the weakening screening or judgment result, and the method is as follows: The blood protein marker assessment submodule, the concentration measurement characteristics of several blood protein markers, judges the measurement results of each blood protein marker, and judges the results below the measurement threshold as positive, and makes a combined judgment on the results of each blood protein marker, wherein the results of any two blood protein markers being positive are judged as hematologically positive; The frailty phenotype index assessment submodule judges the test results of several frailty phenotype index data, and assigns ≥3 points as positive-frail stage, 1-2 points as positive-pre-frail stage, and 0 points as negative-no frailty; The calculation and judgment module is used to determine the assignment results of the blood protein marker assessment submodule and the frailty phenotype index assessment submodule singly or in combination. The calculation module uses the assignment results of the blood protein marker assessment submodule for judgment alone; or, the calculation module makes a combined judgment on the judgment and evaluation assignments of the blood protein marker assessment submodule and the frailty phenotype index assessment submodule. If both are negative, the result is judged to be no frailty; the result of hematology positive + phenotype positive-frail stage is judged to be frail; the result of hematology positive + phenotype positive-pre-frailty is judged to be pre-frailty; the result of hematology negative + phenotype positive-frail stage is judged to be frail; the result of hematology negative + phenotype positive-pre-frailty is judged to be pre-frailty; the result of hematology positive + phenotype negative-no frailty is judged to be questionable, and the result is output by the result output module.

7. The method for using a rapid screening model for frailty according to claim 6, characterized in that: The changes in the blood protein marker indicators of interferon-γ, granulocyte colony-stimulating factor, and tumor necrosis factor-α contained in the blood protein marker assessment submodule in the basic data module are obtained by enzyme-linked immunosorbent assay, Luminex-based multi-analysis spectrum analysis, single-molecule protein array detection, lateral flow immunoassay, nucleic acid aptamer technology, and proteomics determination.

8. The method for using a rapid screening model for frailty according to claim 6, characterized in that: The characteristic indicators such as decreased grip strength, weight loss, fatigue, decreased gait speed, etc. included in the frailty phenotype assessment submodule in the basic data module are obtained through on-site consultation, online or terminal device questionnaires, or on-site testing.

9. The method for using a rapid screening model for frailty according to claim 6, characterized in that: In the calculation and judgment module, the change result of a single indicator is first judged, and then various indicators are combined to set a certain threshold. A single hematological indicator is used for judgment, or a combination of hematology and frailty phenotype indicators is used for comprehensive judgment, and the result is input into the terminal device or online tool.

10. The method for using a rapid screening model for frailty according to claim 7, characterized in that: Granulocyte colony stimulating factor and asthenia phenotype can be used alone or in combination.

Images